British drugmaker AstraZeneca said Wednesday it had gained an exclusive option to acquire two type 2 diabetes drugs being developed by a unit of Japan's Astellas Pharma Inc <4503.T>.

The drugs are PSN821, which is currently in Phase II clinical trials and PSN824, which is poised to enter clinical trials.

Financial terms were not disclosed.

(Reporting by Edwina Gibbs; Editing by Joseph Radford)